Encouragement to pharmaceutical companies to register medicines commonly used in Named Patient Programmes

The
Icelandic Medicines Agency (IMA) hereby publishes a list of the most commonly
prescribed medicinal products in Named Patient Programmes (NPPs) in April 2020.
The list only includes approved prescriptions.

The purpose
of publishing this information is to encourage pharmaceutical companies to
apply for marketing authorisations and market the products listed, or
comparable medicines. The advantage of having a medicinal product authorised
and marketed, is that NPP prescriptions are usually not approved by IMA if a
comparable medicinal product with an MA is marketed. It is therefore beneficial
for all parties involved to have proper registration for the medicinal products
that are sold in Iceland. Benefits for users include updated information in
Icelandic, for both healthcare professionals and patients.

Most of the
medicinal products listed below are absent from the market, whereas a few of
them (starred) are temporary substitutions for registered medicinal products.

This list
only includes medicinal products used in NPPs prescribed to individuals, but
neither includes unregistered medicines used at hospitals and health
institutions, nor medicines prescribed by veterinarians.